As one of Malaysia’s main commodities, the natural gas industry has a significant impact on the economy through various channels. The analysis in this paper provides background research for a project titled the Malaysia-Social Economic Impact Study (M-SEIS) sponsored by the Malaysian Gas Association (MGA) undertaken by IDEAS from October 2019 to February 2020.
The natural gas industry is a major contributor to the public finances, providing over a major source of government revenue. This is set to continue as we estimate that natural gas will contribute nearly RM400 billion to the public finances over the next decade.
Projek Pantau was originally intended to continue for the full five years of the government’s term in office, but following the change in government we needed to rethink our approach. Since there were not many major developments since the December Report Card and the change of government in February 2020, this Final Report Card looks back over the two years of the PH government and highlights the most important promises, including those that were achieved, those that were in progress and those that had fallen behind. The intention of the Final Report Card is also to highlight the current government areas in which they should focus their efforts to ensure further progress in reforming Malaysia’s institutions.
For this Report we have decided to focus on 34 high priority promises. This Report is not intended to provide a fully comprehensive account of all of PH’s policy commitments, but instead seeks to highlight a selection of the most important issues.
This whitepaper was commissioned to investigate the current situation of rare diseases in Malaysia. Due to the perceived rarity of such conditions, the rare disease community was often marginalized, and the lack of a holistic policy on rare diseases impacted how these diseases were managed. These developments resulted in early mortality and severe morbidity, including the learning and physical handicapping of patients with rare diseases. In short, rare diseases remain under diagnosed, underfunded and face many unmet needs Although some steps were taken to address these issues, including the provision of funding for drugs for selected conditions over the last few years, more needs to be done to match the pace of how these diseases are managed in regional countries and global rare disease community to ensure equity in healthcare. Through extensive consultations with various stakeholders and surveys of patient groups and their families, this whitepaper addresses key areas that need to be reviewed to improve not only the healthcare mechanism but also social, ethical, legal and financial management as well as the governance framework for Rare Disease (RD).